drugset / Trial / NCT03983980

Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002)

NCT03983980 ↗

Phase 3 Completed 515 enrolled Organon and Co IQVIA Biotech · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a randomized double-blind vehicle-controlled Phase 3 study to evaluate the efficacy and safety of topical tapinarof cream, 1% once daily for the treatment of plaque psoriasis in adults. Approximately 500 adult subjects with plaque psoriasis will be randomized 2:1 to receive either tapinarof cream, 1% or matching vehicle cream once daily for 12 weeks.

Timeline

Start
2019-06-06
Primary completion
2020-05-13
Completion
2020-05-29

Outcome

Met primary endpoint

registry analysis (superiority test); Tapinarof (DMVT-505) Cream Group vs Vehicle Cream Group; p <0.0001; Risk Ratio (RR) 6.10; Cochran-Mantel-Haenszel NCT03983980 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Tapinarof Other / unclassified 1 % Topical

Indications